metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results	deaths (OS) E	progression or deaths (PFS) E	RFS/DFS E
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
versus docetaxel
	sotorasib
	CodeBreaK 200, 2022 NCT04303780	RCT	metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)	oral sotorasib (960 mg daily)	intravenous docetaxel (75 mg/m2 every 3 weeks)	KRAS G12C-mutated NSCLC who progressed after prior platinum-based chemotherapy and a checkpoint inhibitor	169 / 151	NA	conclusif
	sotorasib NICE ITC 1 unpublished	IND	metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)	sotorasib	docetaxel monotherapy	SLECT 1 patients with KRASmutated (including KRAS p.G12C -mutated) NSCLC	-/-	NA	suggested
	sotorasib NICE ITC Flatiron unpublished	IND	metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)	sotorasib	docetaxel monotherapy		-/-	NA	suggested
versus no control (uncontrolled study)
	sotorasib
	CodeBreaK 100, 2021 N Engl J Med 2021 Jun 24;384(25):2371-2381. NCT03600883	DESC	KRAS gene alteration defined cancer, metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)	otorasib, administered orally at a dose of 960 mg once daily		patients with KRAS p.G12C-mutated advanced NSCLC previously treated with standard therapies	124	NA	no results